Modes of drug elimination and bioactive metabolites

Shruti Chillistone

Jonathan G Hardman

Learning objectives

After reading this article, you should be able to:

- describe the phases of metabolism
- list the routes of drug excretion
- discuss the factors which affect these processes

Abstract

Drug elimination is the removal of active drug from the body. Metabolism takes place largely in the liver and produces water-soluble metabolites which can be excreted in the bile or urine. Metabolism may also produce active or toxic metabolites or a pharmacologically active drug from an inactive prodrug. Most volatile anaesthetics are excreted unchanged via the lungs. Drug elimination can be affected by factors such as first-pass metabolism, genetic variants and various disease processes. Knowledge of these processes will allow better prediction of pharmacokinetics in practice.

Keywords Clearance; excretion; metabolism; pharmacokinetics

Royal College of Anaesthetists CPD Matrix: 1A02

Drug elimination is the removal of active drug from the body and comprises the pharmacokinetic processes of metabolism and excretion. In most cases, the role of drug metabolism is to produce a more polar (water-soluble) molecule that can then be excreted in the bile or urine, the main routes of drug excretion. However, not all drugs are metabolized; some are excreted unchanged. Other routes of drug excretion include the lungs, saliva, sweat, tears, breast milk and hair.

Clearance

Clearance represents the notional volume of blood cleared of the drug per unit time. Drug elimination is often a first-order process, such that the rate of drug removal depends upon its plasma concentration. For most drugs, the total body clearance is the sum of hepatic and renal clearance, but for some drugs clearance by the lungs may be significant (e.g. volatile anaesthetic agents).

Total clearance (Cl) is calculated by dividing the mass of drug that enters the systemic circulation by the area under its plasma concentration vs time curve (AUC).

$$\mathrm{Cl} = \frac{\mathrm{DOSE}}{\mathrm{AUC}}$$

At steady state, when the blood concentration of a drug is constant, the amount entering the blood per unit time (i.e. the dose) must be the same as the amount leaving the body (i.e. the clearance). Thus, for infused drugs, the clearance can be calculated from the infusion rate and the steady state concentration.

Clearance = Drug infusion rate/Steady state drug concentration.

For intermittent drug dosing, a similar relationship exists.

Metabolism

Drug metabolism is largely (though not exclusively) handled by the liver. There are two phases of metabolism: I and II (Figure 1).

Phase I (non-synthetic)

Phase I reactions include oxidation, reduction and hydrolysis. The most important of these is oxidation. Many oxidative phase I reactions result from the activity of cytochrome P450, a non-specific enzyme system residing in the endoplasmic reticulum. Other enzymes involved in phase I metabolism include the mono-oxygenase system, alcohol dehydrogenase, aldehyde dehydrogenase, monoamine oxidase, peroxidase, NADPH-cytochrome P450 reductase, reduced cytochrome P450, esterases and amidases.

Some phase I processes take place in either the plasma or in other tissues. Suxamethonium is metabolized by hydrolysis in the plasma, catalysed by plasma cholinesterase. Genetic variants of this enzyme may lead to prolonged drug action and are discussed in greater detail below. Atracurium is metabolized by lung and plasma esterases but also undergoes spontaneous degradation in a pH and temperature dependent manner (Hoffman elimination) to form a tertiary amine (laudanosine). Remifentanil is metabolized by non-specific plasma and tissue esterases. Other tissues, including gastric mucosa and the lung, also metabolize drugs (Table 1).

Phase II (conjugation or synthetic)

Phase II reactions involve conjugation of the drug; such reactions occur after phase I chemical modification and render the drug metabolite water soluble. The drug molecule becomes chemically bound to a small molecular group (e.g. amino, hydroxyl, thiol, sulphate, glutamate, acetate, methyl and most commonly, glucuronide).

The enzymes involved in drug metabolism can be induced or inhibited by certain drugs and other substances (Table 2). This can give rise to clinically important drug interactions leading to therapeutic failure, drug toxicity or tolerance.

Bioactive metabolites

Metabolism usually reduces the activity of a drug. However, in some cases, it leads to the conversion of one pharmacologically

Shruti Chillistone *FRCA is a Consultant Anaesthetist at Nottingham University Hospitals NHS Trust, Nottingham, UK. Conflict of interest: none declared.*

Jonathan G Hardman *DM FRCA is Professor of Anaesthesia at the University of Nottingham and Honorary Consultant Anaesthetist, Nottingham University Hospitals NHS Trust, Nottingham, UK. Conflict of interest: none declared.*

Please cite this article in press as: Chillistone S, Hardman JG, Modes of drug elimination and bioactive metabolites, Anaesthesia and intensive care medicine (2017), http://dx.doi.org/10.1016/j.mpaic.2017.06.005

Phase I and phase II drug metabolism



Figure 1

Reactions taking place in the lungs

Reaction	Drug	Metabolite
Phase I reactions		
Oxidation	Phenobarbitone	5-ethyl-5-barbituric acid
	Nortryptyline	Desmethylnortryptyline
Reduction	Nitrazepam	7-aminonitrazepam
Hydrolysis	Acetylcholine	Choline and acetate
Phase II reactions		
Methyltransferase	5-hydroxytryptamine	5-N-methyl-5-hydroxytryptamine
Catechol-O-methyltransferase	Isoprenaline	3-O-methylisoprenaline

Table 1

List of liver enzyme inducers and inhibitors

Enzyme inducers	Enzyme inhibitors
Alcohol (chronic)	Alcohol (acute)
Barbiturates	Amiodarone
Carbemazepine	Cimetidine
Griseofulvin	Ciprofloxacin
Phenytoin	Dextropropoxyphene
Rifampicin	Etomidate
Volatiles	Erythromycin
	Fluconazole
	Metronidazole

Table 2

active substance to another active substance. This has the effect of prolonging drug action. An example of this is in morphine metabolism. One of its metabolites, morphine-6-glucuronide, is 13 times more potent than morphine and has a similar duration of action. Metabolism may also lead to the conversion of a pharmacologically inactive substance to an active one. These inactive substances, reliant on metabolism for their pharmacological effects, are termed prodrugs. Examples include diamorphine, parecoxib and enalapril.

Phase I oxidation may also lead to the formation of highly reactive, toxic metabolites (epoxides) that bind irreversibly to cell constituents. Glutathione in the liver combines with epoxides rendering them inactive and is an important defence mechanism against hepatic damage.

First-pass effects

Oral bioavailability (the proportion of orally administered drug entering the systemic circulation compared with the same dose given intravenously) depends not only upon the ability of a drug to penetrate the gut mucosa, but also upon the extent to which the drug is metabolized either by enzymes in the gut wall or in the liver. This metabolism, which occurs before oral drugs are able to reach the systemic circulation, is known as first-pass metabolism. Drugs with significant first-pass metabolism include morphine, lidocaine, glyceryl trinitrate and salbutamol.

Genetic variants

Drug responses are sometimes governed by heredity. Some of the variations which are relevant to anaesthetists are listed below.

Acetylator status

Acetylation is a phase II metabolic pathway in the liver for many drugs that possess a $-NH_2$ group and include isoniazid, hydralazine, and sulphasalazine. Different isoenzymes acetylate at either a fast or slow rate, leading to pharmacokinetic differences between individuals.

Pseudocholinesterase deficiency

Suxamethonium is hydrolysed in the plasma by plasma pseudocholinesterase. However, genetic variability can lead to prolonged neuromuscular block. Ten different genotypes are known. Heterozygotes for the normal gene have a mildly prolonged block, whereas a small fraction of the population have a genotype which may confer a block of several hours.

Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency

G-6-PD activity maintains erythrocyte glutathione in its reduced form, which is necessary to keep haemoglobin in its reduced (ferrous) rather than ferric state (methaemoglobin). Individuals who are G-6-PD deficient may suffer acute haemolysis if exposed to certain oxidant drugs, including quinolones, sulphonamides and sometimes aspirin.

Biliary excretion

The bile is the route of excretion for high molecular weight compounds (generally greater than 300) such as the steroid-based muscle relaxants. Secretion into the biliary canaliculus is an active process and therefore subject to inhibition and competition. Drugs may be excreted unchanged or as conjugated metabolites. Once in the digestive tract, lipid-soluble drugs may be reabsorbed unchanged and glucuronide conjugates may be hydrolysed by bacterial glucuronidase and reabsorbed. The drug can then be extracted from the portal circulation by the liver and

Please cite this article in press as: Chillistone S, Hardman JG, Modes of drug elimination and bioactive metabolites, Anaesthesia and intensive care medicine (2017), http://dx.doi.org/10.1016/j.mpaic.2017.06.005